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Abstract
Complicated skin and soft tissue infections (cSSTIs) are a diverse group of infections, with a range of presentations and microbiological
causes. Hospitalization is common for patients with a cSSTI, which is treated by drainage of the affected area and with antibiotics. Host
factors such as co-morbidities, and microbial factors, in particular drug resistance, complicate the management of these infections.
Methicillin-resistant Staphylococcus aureus (MRSA) is an important cSSTI pathogen in Europe, and its involvement can be associated with
poor patient outcomes. European guidelines recommend vancomycin, teicoplanin, linezolid, daptomycin, tigecycline or ceftaroline for
treatment of MRSA cSSTIs. Of primary importance when treating cSSTIs is the agent’s clinical efﬁcacy against the causative pathogens, as
well as its bioavailability in the skin and associated structures. Linezolid is well-suited for the treatment of MRSA cSSTIs; it achieves high
penetration into skin and soft tissues with 100% oral bioavailability, and therefore enables an intravenous to oral switch and outpatient
treatment. When eligible patients are offered oral therapy the associated length of hospital stay and overall costs can be reduced. Linezolid
has demonstrated clinical efﬁcacy and favourable outcomes in patients for the treatment of MRSA cSSTIs including the treatment of lower
extremity infections. Furthermore, efﬁcacy has been documented in key deﬁned populations, such as individuals with renal impairment and
the obese. The safety proﬁle of linezolid is well-documented, making this antibacterial a viable choice for the treatment of MRSA cSSTIs.
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Introduction
Bacterial skin and soft tissue infection (SSTI) is a common
cause of morbidity and mortality in both the community and
hospital settings. Staphylococcus aureus is the predominant
cause of these infections [1] and methicillin-resistant S. aureus
(MRSA) is an important contributory factor in the develop-
ment of complicated SSTIs (cSSTIs). This review addresses the
deﬁnition and aetiology of cSSTIs and evaluates recent
advances in the ﬁeld of managing this heterogeneous group
of conditions. In particular, we explore the situation in Europe
with regard to MRSA and its treatment with linezolid, which is
indicated for cSSTIs that are caused by Gram-positive bacteria
[2].
Deﬁnition of cSSTI
Invasion of the epidermis, dermis and subcutaneous tissue by
bacteria leads to SSTIs, which can produce a variety of clinical
presentations [1]. The severity of these infections is dependent
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on a series of factors, and the clinical spectrum ranges from
mild forms to more life-threatening variants [3]. Otherwise
healthy individuals with severe infections can be affected by
SSTIs, as can patients with major co-morbidities and relatively
minor infections [1].
In many cases, the severity of the SSTI necessitates
hospitalization [4]. When the infection penetrates to the
deeper subcutaneous tissue and/or surgery is required, it is
considered ‘complicated’ (cSSTI) [5]. Included within this
category—which sits at the extreme end of the clinical
spectrum—are major cutaneous abscess, cellulitis, erysipelas,
infected decubitus ulcer, infected ischaemic ulcer, infected
venous stasis ulcer, bite-related infection, wound infection,
surgical-site infection and trauma infection [1,6]. Compli-
cated SSTIs can threaten lives and limbs, and therefore
require early recognition and prompt management. Aside
from surgery and drainage of the affected tissue, treatment
for cSSTIs is centred on appropriate antibiotic therapy [1].
Recognition of cSSTI
Numerous species of microorganisms colonize the skin, and
when broken, the skin can be penetrated by a wide variety of
bacteria [7]. Infection, which is distinct from colonization,
develops when microbial pathogenicity overcomes the host’s
immunological defences [8]. Local, systemic and microbial
factors interact in a dynamic process to complicate SSTIs, and
clinical recognition of these risk factors is important (Table 1).
These processes account for the heterogeneity of cSSTIs, as
previously discussed [1,8–11].
In some cases, cSSTI can present as a septic illness in
previously ﬁt and healthy individuals who are not immuno-
compromised. These are typically caused by highly pathogenic
strains of common organisms, for example S. aureus express-
ing Panton-Valentine leucocidin (PVL) or toxigenic strains of
Streptococcus pyogenes [11]. Typically, these infections spread
rapidly and are medical emergencies that require prompt
clinical recognition (which in most cases is driven by the
observation of raised inﬂammatory markers); urgent surgical
debridement should be carried out, and high doses of
antibiotics should also be administered.
Local warning signs for cSSTIs include vascular insufﬁciency,
increased depth of infection into the surrounding tissues, spread
toward contiguous structures and involvement of foreign bodies
(e.g. prostheses, grafts) [1,9]. Peripheral vascular disease is also
associated with an increased risk for cSSTI. It is a predictor of
impaired wound healing and is independently associated with
major leg wound complication after saphenous vein harvest for
coronary artery bypass graft procedures [12]. Vascular insufﬁ-
ciency can severely limit drug penetration to the site of bacterial
infection, potentially leading to inadequate drug concentrations,
clinical and microbiological treatment failure and the develop-
ment of antimicrobial resistance [13]. Peripheral vascular
disease is further associated with impaired renal function,
hypertension and diabetes, which are also independently
associated with impaired wound healing [12,14,15].
A series of systemic host risk factors may also escalate the
recognition of cSSTIs (Table 1). Factors such as more advanced
age, alcoholism, chronic renal failure, cardiovascular disease,
cirrhosis, diabetes mellitus, human immunodeﬁciency virus
infection, immunosuppression, malnutrition, neuropathy, nico-
tine addiction, obesity, sedentary lifestyle, peripheral vascular
insufﬁciency and solid and haematological tumours have all been
shown to inﬂuence the course of disease [8]. Themost common
risk factors for cSSTIs are hospitalization within the past
6 months and antibiotic use within the past 30 days [5].
Most often, cSSTIs are due to monomicrobial infection
caused by Gram-positive or Gram-negative bacteria; however,
they can also be polymicrobial [1], with a mixture of
Gram-positive and Gram-negative bacteria comprising nearly
one-ﬁfth of infections in a US study [10]. Polymicrobial
infections occur most often where tissue vascular perfusion
is compromised, such as during infection of ischaemic or
venous ulcers and in patients previously treated with antibi-
otics [1]. When more than one species of bacteria is involved
in cSSTI there can be a synergistic effect, which can increase
the pathogenicity and present a further challenge for clinical
management [16,17].
Another microbial factor to consider in the recognition of
cSSTIs is toxin production. Staphylococcus aureus, for example,
commonly colonizes the skin and nasal membranes; however,
its genome contains numerous potential virulence factors, such
as adhesins, exoenzymes and exotoxins, which can result in
varying degrees of pathogenicity. Production of the PVL toxin,
TABLE 1. Recognizing complicated skin and soft tissue
infections: local, systemic and microbial warning signs
Local [1,9] Systemic [8] Microbial [1,10,11]
Vascular
insufﬁciency
Depth of tissue
penetration
Involvement of
contiguous
structures
Involvement of
foreign bodies
(e.g. prosthesis,
grafts)
Alcoholism
Chronic renal failure
Cardiovascular disease
Cirrhosis
Diabetes mellitus
Elderly age
Human immunodeﬁciency
virus infection
Iatrogenic immunosuppression
Malnutrition
Neuropathy
Nicotine addiction
Obesity and sedentary lifestyle
Peripheral vascular insufﬁciency
Solid and haematological
tumours
Antibacterial resistance
Polymicrobial infection
Toxin production
(e.g. Panton–Valentine
leukocidin)
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 4), 3–18
4 Clinical Microbiology and Infection, Volume 20 Supplement 4, April 2014 CMI
which can be produced by both methicillin-susceptible
S. aureus (MSSA) and MRSA, has been associated with invasive
strains [18]. Presence of the lucF-PV gene, which encodes PVL,
is a signiﬁcant predictor of the need for incision and drainage,
compared with non-PVL MSSA [19]. PVL-producing MRSA is
particularly prevalent in infections that have been acquired in
the community [11]. b-Haemolytic streptococci can also
produce toxins that may both potentiate their virulence and
affect the soft tissues [1].
Intrinsic microbial factors, such as antimicrobial drug
resistance, can be associated with an increased risk of
cSSTI. Complicated SSTIs acquired in the healthcare setting
are often caused by drug-resistant bacteria [20,21], and MRSA
is commonly implicated [10]. Macrolide resistance by Group A
and B streptococci is irregularly distributed in Europe, whereas
vancomycin-resistant Enterococcus spp., although uncommon
outside the USA [22], has shown an increased prevalence in
Europe over recent years [23]. Macrolide, lincosamide and
streptogramin B resistance is a feature of certain strains of
S. aureus, which is brought about by modiﬁcation of the
erythromycin ribosomal methylase genes. In some strains, this
resistance can be induced by clindamycin, precluding its
therapeutic efﬁcacy [24].
MRSA: An Important Pathogen in Europe
Globally, the most common cause of cSSTIs is S. aureus [1].
According to the SENTRY antimicrobial surveillance pro-
gramme, which has monitored SSTI since 1997, S. aureus is
rated as the predominant pathogen in all regions across North
America, Latin America and Europe. Rates of MRSA varied
among these continents, with the highest proportion found in
North America [25]. Staphylococcus aureus is also the most
common cause of cSSTIs in Europe. A study of more than 3000
cSSTI-associated isolates that were sampled from 19 countries
in and around Europe during 2008–2009 found that almost
one-third were S. aureus and, of those, approximately one-half
were MRSA [26].
The past 10 years have shown changes in the epidemiology of
MRSA in Europe; however, recent data submitted to the
European Antimicrobial Resistance Surveillance (EARS) Net-
work by 28 participating countries suggested that, overall, MRSA
accounted for 16.7% of all S. aureus isolates. In ten of these
countries the proportion ofMRSAamong S. aureuswas 10–25%.
Rates of MRSA of >25% were reported from Cyprus, Greece,
Italy and Malta, and MRSA accounted for >50% of S. aureus
isolates in Romania and Portugal (Fig. 1) [27]. Although the
countries of northern Europe have a low prevalence of MRSA,
possibly due to major ‘search and destroy’ programmes in these
countries [28], MRSA continues to be a signiﬁcant and increasing
public health problem in Europe [29] and many strains of
community origin are imported by travellers.
Although cSSTIs are largely caused by species of Gram-
positive bacteria [23], Gram-negative organisms are more
common in surgical-site infections [30]. After S. aureus, the
SENTRY programme (1998–2004) identiﬁed Pseudomonas
aeruginosa as the second most important pathogen in the
aetiology of SSTI, followed by Escherichia coli and Enterococcus
spp., although these were exclusively in hospitalized patients
[25]. After sampling pathogens from cSSTI patients in 13
countries across Europe during 2003–2008, Sader et al. [23]
FIG. 1. Staphylococcus aureus: percentage
of invasive isolates resistant to methicillin
(MRSA), by country, European Union/
European Economic Area countries,
2008–2011 [27]. Reproduced with
permission from the European Centre
for Disease Prevention and Control.
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isolated S. aureus from the majority (71.1%) of infections,
followed by b-haemolytic streptococci (10.5%) and entero-
cocci (9.3%) [23]. Data from an Italian study identiﬁed the
Enterobacteriaceae Proteus mirabilis in 1% of cSSTIs in a
population of hospitalized patients [31]. Although less fre-
quent, other non-bacterial microbes can lead to cSSTIs,
particularly in travellers, and, in certain circumstances, it is
important to consider fungal causes, such as invasive aspergil-
losis, mucormycosis and other mycoses in immunocompro-
mised patients [1,32–34].
Risk Factors for MRSA Infection
Risk factors for MRSA infection relate to both the health of the
host and external inﬂuences (Table 2) [35–44]. Previous MRSA
infection or colonization [35,43], previous exposure to
antimicrobial agents [44], advanced age [41] and chronic open
wounds [36,42] are all associated with an increased risk of
MRSA in hospitalized patients. Also, underlying diseases or
conditions such as chronic renal disease [41], diabetes [37,41],
peripheral vascular disease [45], cardiovascular disease [41]
and immunosuppression [37] are frequently seen in patients
who have MRSA. When stratifying the risk of MRSA in patients
with cSSTIs, many of these factors have signiﬁcant discrimina-
tory value for differentiating from non-MRSA cSSTIs [46].
With regard to external factors, risk of MRSA is associated
with repeated contact with the healthcare system, including
long-term care, skilled nursing homes, home care and
haemodialysis centres [39,41]. Other factors include intensive
care unit (ICU) admission [38] and invasive procedures, such
as dialysis [40], central venous catheterization [37] and
parenteral drug use [41].
Disease Burden and Outcomes
MRSA infections are commonly classiﬁed as either healthcare-
associated (HA-MRSA) or community-associated (CA-MRSA),
although the distinction between the two is becoming blurred
[1]. In addition to healthcare-associated infections, new MRSA
strains have recently emerged as livestock-associated, which
have the potential to be imported into hospitals, adding to the
disease burden [47]. MRSA that is acquired in the community
typically affects the young and healthy, commonly affects the
skin and soft tissues and spreads easily in the community and
among families. Although PVL genes are present in CA-MRSA,
this infection tends to be more responsive to antibiotics than
HA-MRSA [48], and is associated with a more favourable
prognosis [49]. HA-MRSA typically affects the elderly or
critically ill. It can occur following an individual’s exposure to
an inpatient or primary-care setting and is often resistant to
treatment with multiple antibiotics, making the selection of
efﬁcacious agents limited [48]. The main burden of MRSA is
endured within the healthcare system in Europe, but
CA-MRSA has become a signiﬁcant public health threat in
the Americas and increasingly so in Europe, even among
healthy individuals who lack classic risk factors for MRSA [50].
A US study that evaluated the impact of CA-MRSA found that,
compared with CA-MSSA, it is associated with a longer
duration of antibiotic therapy by an additional 2 days, a
signiﬁcantly lower cure rate (61% versus 84%, p <0.001) and a
greater risk of recurrence (18% versus 6% p <0.015) [51].
A variety of sources are implicated in the transmission of
CA-MRSA and certain subsets of populations are at higher risk
of acquiring this form of the infection, such as contact sports
players, children, military personnel, drug users, prisoners,
men who have sex with men, human immunodeﬁciency
virus-infected patients and those in crowded housing [52].
Exposure to a variety of healthcare services, such as infusion
or dialysis centres, nursing homes and other long-term care
centres, is also an important source of MRSA [39].
Community-acquired MRSA is much more common in the
USA [52] and is associated with increased prevalence of SSTIs
[53]. In Europe, although CA-MRSA is not considered
important, this trend may now be shifting [1,47,48,52]. The
ﬁrst report of CA-MRSA in the continent came from France in
1999 [54]. Data suggest that the rate of CA-MRSA in France
has risen [52], with an increase from 4% in 2000 to 17% in
2003 [55]. In the UK, although the incidence in England and
Wales is low (accounting for only 0.005% of all referred MRSA
isolates between 2002 and 2005 [56]), there was a 46% rise in
presumptive CA-MRSA from 332 cases in 2000 to 484 cases in
2004 [57].
TABLE 2. Common risk factors for methicillin-resistant
Staphylococcus aureus (MRSA) infection in complicated skin
and soft tissue infections
Risk factors
Previous history of MRSA infection or colonization [35,43]
Previous use of antimicrobial agents [44]
Advanced age [41]
Chronic open wounds [36,42]
Underlying diseases or conditions
Chronic renal disease [41]
Diabetes [37,41]
Peripheral vascular disease [45]
Cardiovascular disease [41]
Immunosuppression [37]
Repeated contact with the healthcare system (including hospitals, long-term care,
nursing homes, home care, haemodialysis centres and physician’s ofﬁces) [39,41]
Intensive care unit admission [38]
Invasive procedures (such as dialysis [40] and central venous catheterization
for >24 h) [37]
Parenteral drug use [41]
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In-hospital mortality rates in patients with cSSTIs have been
reported in outcome studies and show a wide range, from
0.4% to 26.7% [5,10,20,21,38,58–63]. This could be related to
differences in patient populations (e.g. ICU versus non-ICU),
infection types or severity, presence of resistant pathogens or
how the infections were managed [5]. Data describing
mortality outcomes in hospitalized patients with cSSTIs in
Europe are limited. In a pan-European point prevalence study
conducted on 1 day in 1992 (The European Prevalence of
Infection in Intensive Care (EPIC) Study), Ibelings et al. [38]
reported a mortality rate of 26.7% in ICU patients with wound
infections caused by MRSA. The REACH study group
conducted a large, retrospective, observational study of
patients with cSSTIs (n = 1996) from 129 hospitals in ten
European countries between 2010 and 2011 [62,64]. Overall,
37% of the patients with cSSTIs required surgical intervention
and 6.5% were admitted to the ICU; 68 patients died,
representing a mortality rate of 3.4% [62,64].
Edelsberg et al. [60] examined predictors of mortality in a
multivariate analysis. Patients with cSSTIs who experienced
failure of initial antibiotic therapy were three times more likely
to die in hospital compared with patients for whom initial
therapy was successful (1.7% versus 0.5%; p <0.01). Other
signiﬁcant predictors of mortality included advanced age,
initiation of antibiotic therapy in the ICU and receipt of
vasoactive medications in the hospital (all p <0.01) [60]. A
higher score on the Charlson Co-morbidity Index, which is
used to stratify patients into groups depending on their
particular co-morbidities, has been found to be associated with
an increased likelihood of treatment failure in patients with
cSSTIs [60]. Hospital mortality rates have also been shown to
be higher in cSSTI patients with healthcare-associated infec-
tions versus community-acquired infections [20,63] and in
patients with MRSA versus non-MRSA infections [10,61].
When the infecting pathogen for a cSSTI is MRSA, there is an
increased disease burden, as compared with non-MRSA
cSSTIs. In particular, the mortality risk is signiﬁcantly higher
and the hospital length of stay is signiﬁcantly longer with MRSA
infections [10].
Diagnosis
As with all infections, in cSSTI, clinical assessment of disease
severity is an important step in diagnosis. This can be achieved
by qualitative assessment of the causative pathogen and by
quantifying the bacterial load [3,65]. Microbiological diagnosis
and susceptibility testing may be of increasing importance in
the era of multidrug-resistant bacteria, and are crucial steps in
promoting appropriate antibiotic prescribing. Swabs of pus or
tissue samples from open wounds, where possible, may
provide the best diagnostic value [7]. If a deeper tissue
specimen is needed, microbiological samples taken from
aspirated exudates and from a biopsy of deep tissue should
be obtained after debridement and cleansing of superﬁcial
tissue [3]. These materials are expected to be the most
appropriate for microbiological diagnosis [3].
Clinical outcomes, especially the duration of hospital stay,
are affected by the initial choice of antibiotic. An early
assessment of the patient’s MRSA status is therefore impor-
tant [10,46]. Conventional microbiological techniques,
although valuable for establishing the initial diagnosis, are
time consuming and can cause a delay in diagnosis of up to
5 days. When MRSA infection is suspected, any delay in the
diagnosis can be costly, because of the need to isolate patients
with a suspected infection from other patients on the hospital
ward [66]. Once S. aureus has been conﬁrmed (Gram staining,
followed by culture on mannitol salt agar), culture on
chromogenic agar can differentiate MRSA, at an estimated
cost of €2 per test and a further delay of 2–3 days to obtain
the result [67].
Staphylococcus aureus acquires resistance to methicillin and
b-lactams by the expression of the mecA gene, which encodes
variant penicillin-binding proteins. Rapid, commercially avail-
able PCR-based tests can detect this gene, and several
molecular-based tests have been approved for the detection
of MRSA in nasal swabs and wound clinical samples [67]. These
assays have much higher reagent and instrument costs, yet
they provide shorter turnaround times. Several routine
molecular MRSA diagnostic tests are available [67,68]. A new
assay targets three distinct regions of the MRSA genome
(mecA, nuc and the SCCmec.orfX junction), yet this method
does not provide signiﬁcantly greater sensitivity or speciﬁcity
than the routine PCR-based assays [69]. In patients with SSTIs
that are caused by invasive fungal infections, many traditional
(e.g. histopathology and culture) and new (e.g. PCR and
antigen-based) techniques are available that enable rapid
diagnosis [70].
Aside from microbiologically based and molecular-based
protocols, imaging techniques can provide structural informa-
tion about deep tissue cSSTIs. To differentiate necrotizing
from non-necrotizing infections, imaging has the ability to
detect oedema that extends along the fascial plane [6,71].
Radiography can be used to detect the gas in tissues that is
indicative of necrotizing infection, as can computed tomogra-
phy, and ultrasonography can be used to guide diagnostic and
therapeutic aspiration of abscesses. Magnetic resonance imag-
ing has particularly sensitive diagnostic value for imaging and
can be used to determine the extent of deep tissue involve-
ment [3].
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Management of MRSA cSSTIs and
Treatment Guidelines in Europe
Management of cSSTIs
Clinical management of cSSTIs is achieved using a combination
of surgical, supportive and antimicrobial therapies. Surgical
techniques can include the mechanical or chemical debride-
ment of devitalized tissues [1,72] and the use of non-adherent
dressings [73]. For general management, cutaneous abscess is
dealt with primarily by incision and drainage, with antibiotics
indicated for patients who do not respond to these initial
interventions. Antibiotics are also indicated when there is
more extensive disease or the abscess is in an area that is
difﬁcult to drain, for rapid progression of infection, and where
there are signs of systemic illness, co-morbidities or immuno-
suppression [72]. Negative pressure dressings can be used for
infections with excessive exudate or for large wounds [74]. In
some hospitals, vacuum-assisted closure has become routine
for chronic wound treatment [75]. Also, skin grafting, revas-
cularization or reconstructive methods may be necessary after
the infection has been treated [76]. Supportive therapy for
MRSA cSSTIs includes the provision of oxygen, intravenous
(IV) ﬂuids, nutrition and glycaemic control for patients with
co-morbid diabetes [77].
Antibiotic treatment for cSSTIs should address both host
and microbial factors by taking into account the type, site and
severity of infection, patient co-morbidities and local
drug-resistance patterns. Colonization alone with MRSA does
not require systemic antibiotic treatment and should be
distinguished from infection. Although occasionally coloniza-
tion may lead to infection, good antibiotic stewardship
demands that all physicians must consider whether antibiotics
are clinically indicated in every case of SSTI [1].
Treatment guidelines
Several national and international guidelines have set out
recommendations for the treatment of MRSA cSSTIs (Table 3)
[3,72,75,77–82]. The guidelines of the Infectious Diseases
Society of America outline the appropriate antibacterial
treatment for cSSTIs in the era of CA-MRSA. In hospitalized
patients, surgery and appropriate antibiotics are suggested, and
empirical therapy for MRSA should be considered pending the
culture results. Treatment options for hospitalized patients
include vancomycin (IV), teicoplanin (intramuscular; Europe
only), linezolid (oral or IV), daptomycin (IV), tigecycline (IV),
telavancin (IV; USA only), clindamycin (oral or IV) and
ceftaroline (IV) [72,84]. Guidelines in Europe, including those
from the British Society for Antimicrobial Chemotherapy [79]
generally agree with the Infectious Diseases Society of America
recommendations. The Italian Society of Infectious Diseases,
the International Society of Chemotherapy [3], and the Italian
Working Group on Complicated Skin and Skin-Structure
Infections (Gruppo Italiano di Studio sulle Infezioni Gravi) [75]
have produced consensus statements for the treatment of
cSSTIs, as has the Spanish Society of Chemotherapy [81]. The
UK’s National Institute for Clinical Excellence guidelines stress
the importance of using empirical antibiotic therapy with an
agent that is active against locally prevalent strains of MRSA,
and the clinical progress of antibiotic therapy should be
reviewed in light of bacterial culture results [82]. Furthermore,
the UK Health Protection Agency [78] and British Society for
Antimicrobial Chemotherapy working group [48] give speciﬁc
guidance for treating PVL strains of MRSA, which should
TABLE 3. Guidelines for the antibacterial treatment of
methicillin-resistant Staphylococcus aureus complicated skin
and soft tissue infections
Society
Recommendation (graded
level of evidence)a
Infectious Diseases Society of America [72] Vancomycin (A–I)
Linezolid (A–I)
Daptomycin (A–I)
Telavancinb (A–I)
Clindamycinb (A-II/A-III)
Surgical Infection Society [80] Clindamycin (C–I)
Linezolid (C–I)
Erythromycin (C–I)
Italian Society of Infectious Diseases and
International Society of Chemotherapy [3]
Vancomycin (A–I)
Teicoplanin (A–I)
Linezolid (A–I)
Tigecycline (A–I)
Daptomycin (A–I)
Gruppo Italiano di Studio Infezioni Gravi
(GISIG)c [75]
Vancomycin (A)
Teicoplanin (A)
Tigecycline (B)
Daptomycin (C)
Linezolidd (D)
British Society of Antimicrobial
Chemotherapy [79]
Glycopeptides (A–I)
Linezolid (A–I)
Daptomycin (A–I)
Tigecyclinee (B–I)
Spanish Society of Chemotherapyf [81] Linezolid
Daptomycin
Vancomycin
Teicoplanin
Recommendations for the treatment of MRSA are available for Germany [83],
however, these do not provide speciﬁc guidance on the treatment of MRSA
cSSTIs.
MRSA, methicillin-resistant S. aureus; cSSTIs, complicated skin and soft tissue
infections.
aWhere stated, grading has been included and is based on the strength (where
A = good evidence, B = moderate evidence and C = poor evidence) and quality
(where I = evidence from at least one properly randomized, controlled trial,
II = evidence from at least one well-designed, non-randomized trial and
III = evidence from opinions of respected authorities) of evidence.
bDuring pregnancy.
cMethodology adapted from the GRADEWorking Group was applied to assign the
strength level of the recommendation [75].
dLinezolid could be an alternative treatment to glycopeptides despite the low to
medium methodological quality of analysed trials.
eWhere the infection is deemed polymicrobial and where MRSA is considered to
be an important pathogen.
fHigh doses of tigecycline should be considered in cases of moderately severe
polymicrobial infection with MRSA involvement.
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involve the administration of empirical antibiotic therapy with
two agents (chosen from clindamycin, trimethoprim, vanco-
mycin, mupirocin and linezolid), and which should initially be
guided by clinical assessment until deﬁnitive susceptibility
results become available.
Importance of Appropriate Initial Antibiotic
Therapy
As stated above, the administration of appropriate initial
antibiotic therapy with an agent that is active against the
causative pathogen is a cornerstone in the management of
cSSTIs. The timing of when effective treatment is initiated for
these infections is also important for patient outcomes, as
failure to give antibiotics within 8 h of presentation is associated
with prolonged patient hospitalization (>7 days) [85].
Treatment failure in cSSTIs appears to be common, with a
rate of 46.6% in patients (n = 1996) from 129 sites in ten
European countries reported by one study [64]. Treatment
failure that required a change in antibiotic was more common
in nosocomial than non-nosocomial infections (53.3% versus
45.9%) and in patients with co-morbidities than in those
without (49.3% versus 37.1%) [64]. Studies have shown that
when the antibiotic that is initially prescribed to a patient with
a cSSTI fails, adverse clinical outcomes are more likely. For
example, in a population of hospitalized patients with cellulitis/
cutaneous abscess, inadequate empiric antimicrobial therapy
was a risk factor that was independently associated with
clinical failure [86]. Furthermore, in a large, multicentre, US
study of 47 219 patients with cSSTIs, of whom 22.8% failed
initial therapy, there was an associated increase in mortality
(OR 2.91; 95% CI 2.34–3.62) [60]. In a smaller retrospective
study, the authors demonstrated a greater likelihood of
hospital readmission or death within 30 days in the subset of
cSSTI patients with decubitus ulcers who received inappro-
priate initial antibiotic therapy (adjusted OR 11.76; 95% CI
1.30–111.11; p 0.03) [63]. Furthermore, inadequate initial
antibiotic therapy can increase length of hospital stay and
costs [31,58,60]. In a retrospective Italian study, failure of
initial treatment in cSSTIs was estimated to cost €7835 versus
€4989 when the initial antibiotic led to clinical success without
the need for further IV treatment [31]. These data provide
compelling evidence that inappropriate initial antibiotic treat-
ment leads to worse patient outcomes and increased costs;
however, as with all retrospective observational studies, these
associations do not necessarily imply causality.
Clinician awareness of microbial and patient factors asso-
ciated with inappropriate antibiotic therapy for cSSTIs is
important to help guide empirical treatment decisions.
Nosocomially acquired cSSTIs are more likely to be treated
with inappropriate initial antibiotic therapy than commu-
nity-acquired infections [20,21]. Inappropriate treatment,
deﬁned as administration of antimicrobial therapy that has
no activity against the isolated pathogen(s), is also more likely
in patients with direct hospital admission, a device-associated
infection or an infection due to MRSA [20,21,63]. Data from a
large UK hospital demonstrated that inadequate therapy
increased with the severity of the cSSTI [87], conﬁrming that
worse patient outcomes are associated with suboptimal
treatment. Patients with MRSA require different empiric
treatment than those with non-MRSA infections, and yet
accurate tools to aid in stratifying the risk for an MRSA cSSTI
are lacking [46].
Characteristics of Available Antibiotics for
MRSA cSSTIs: Pharmacokinetic Parameters
and Tissue Penetration
Successful management of cSSTIs requires an antibiotic with
intrinsic activity against potential pathogens, as well as an
ability to distribute to tissues of the skin and skin structures
[13,88]. Poor tissue penetration may lead to inadequate drug
concentrations, clinical and microbiological treatment failure
and the development of resistance among bacterial pathogens
[13]. Host factors, such as co-morbidities that might affect the
penetration of the chosen antimicrobial, should therefore be
taken into account when selecting an agent [89–91]. Tissue
distribution of antibiotics can be complicated by vascular
insufﬁciency, which is common in cSSTIs. Underlying co-mor-
bidities, such as vascular disease or diabetes, can lead to the
disruption of normal blood and lymphatic ﬂow and to
devitalized tissues [13].
Antibiotics for the treatment of MRSA cSSTIs have different
pharmacokinetic parameters that affect tissue penetration
(Table 4). Tissue penetration data are available for ﬁve of the
six antibiotics licensed for MRSA cSSTIs in adults in Europe.
These calculations were based on studies in patients with
cSSTIs, patients receiving the antibiotic for another indication,
as well as in healthy volunteers [92–97]. Antibiotics with the
smallest molecular weights have the highest tissue penetra-
tions [93,95]; however, molecular weight is not the sole factor
affecting tissue penetration. A larger volume of distribution
suggests good tissue penetration. Lipophilic drugs and those
with lower protein binding are also more likely to distribute to
the tissues and therefore have higher volumes of distribution
(Table 4) [2,92–103].
Of the treatments that are currently available for Gram-
positive (including MRSA) cSSTIs in Europe, with data from
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randomized controlled trials conducted in MRSA cSSTIs, only
linezolid is available as an oral treatment [104]. Older oral
antibiotics such as doxycycline, cotrimoxazole, fusidic acid,
rifampicin and clindamycin are frequently used clinically, alone
or in combination, but their use is not supported by trial
evidence. When linezolid was administered experimentally in
non-therapeutic oral doses (one 125 mg + one 250 mg tablet)
or IV (375 mg, over 30 min) for 7 days, there were no
statistically signiﬁcant differences between the fasted oral and
IV treatments in the area under the plasma concentration–
time curve to 7 h (AUC0–7) or other pharmacokinetic
parameters [2]. In addition, the speed at which oral and IV
linezolid is absorbed also appears to be roughly comparable
[105]. When prescribed orally, linezolid shows high penetra-
tion to the skin and soft tissues [93,104], with the mean
percentage of penetration into inﬂammatory ﬂuid found to be
104% [93]. In a rat model, linezolid displays a rapid tissue
absorption and homogeneous tissue distribution [106]. In
patients with severe vascular disease, linezolid is effective at
penetrating affected tissue in sufﬁcient concentrations to be
microbiologically active [107,108].
Oral Therapy and Early Discharge
Although an instant serum therapeutic level of antibiotic is
most effectively achieved via IV infusion of the drug, oral
antibiotics allow patients to be effectively treated outside the
hospital without the need for outpatient infusion therapy
[109,110]. The availability of an IV preparation of linezolid, as
well as a highly bioavailable oral formulation, is a signiﬁcant
advantage, as it offers the potential to treat patients effectively
in the inpatient or ambulatory care setting. Oral therapy with
linezolid does not compromise clinical outcomes for MRSA
cSSTI [111]. Deﬁning when to switch patients safely is an
important decision. A survey of clinicians has shown that the
most important factors in determining antibiotic switching are
the patient’s ability to maintain oral intake and the speciﬁc
microbiological aetiology of the infection [112]. While switch-
ing is not suitable for all patients a number of well-established
and validated criteria exist, as shown in Table 5 [113].
Another advantage of oral formulations of effective drugs is
convenience to both the clinician and patient. From a patient’s
point of view, oral treatment is often preferable, if a choice can
be given [114]. Also, oral treatment allows patients to recover
at home with reduced social isolation, enhanced quality of life
and likelihood of an earlier return to work. From the clinician’s
perspective, the ability to discharge the patient home earlier
from a healthcare facility will reduce a range of health-
care-associated infection and non-infection-related complica-
tions [114,115]. For this reason, switching patients from IV to
oral therapy is regarded as a key antimicrobial stewardship
measure aimed at improving the quality of antibiotic use [116].
Indeed, the effectiveness of IV to oral switch in hospitals has
been recommended as a quality indicator [117].
One of the other key priorities for switching from IV to oral
therapy is to reduce the length of a patient’s hospital stay. A
number of factors will inﬂuence whether a patient can be
discharged, and delays can occur for several reasons. Social
issues, such as lack of an identiﬁable caregiver upon discharge,
can delay the process, whereas advanced age, co-morbidities,
the development of sepsis, deconditioning and cardiovascular
TABLE 4. Antibiotics for methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections have different
pharmacokinetic proﬁles and tissue penetration
Molecular weight
Ratio of skin and soft
tissue: plasma
penetrationa (%) Volume of distribution Protein binding (%)
Linezolid 337.4 [2] 104 [93] 40–50 L [2] 31 [2]
Tigecycline 585.6 [101] 74 [95] 7–9 L/kg [101] 71–89 [101]
Teicoplanin 1879.7 [103] 24–77 [92,96] 0.7–1.4 L/kg after 3–6 mg/kg [103] 88–91 (with weak afﬁnity) [103]
Daptomycin 1620.7 [100] 68 [97] 0.1 L/kg [100] 90–93 [100]
Vancomycin 1485.7 [99] 10–30 [94] 0.43–0.9 L/kg [99] 30–55 [99]
Ceftaroline 762.75 [98] Not available 20 L [98] 20 [98]
aIn healthy volunteers or patients.
TABLE 5. Patient eligibility for intravenous to oral switch of
antimicrobial therapy (adapted from Mertz et al. [113])
Eligible for oral switch
Received intravenous antibiotics for >24 h
Afebrile for >24 h (core temperature <38°C, tympanic)
Stable clinical infection
White blood cell count normalizing, not <4 9 109/L or >12 9 109/L
No unexplained tachycardia
Systolic blood pressure ≥100 mmHg
Patient tolerates oral ﬂuids/diet and able to take oral medications with no
gastrointestinal absorption problems
Not eligible for oral switch
Vomiting or severe diarrhoea
Haematological malignancies or neutropenia
Impaired gastrointestinal absorption
Dementia
Osteomyelitis; septic arthritis; central nervous system infection, Staphylococcus
aureus bacteraemia, endocarditis or intravascular infection (e.g. suppurative
thrombophlebitis)
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disorders, are the main factors that can increase the patient’s
length of hospital stay [118]. However, in many patients the
lack of an indication for early switch to oral treatment and/or
the absence of an effective discharge plan can often reduce the
potential for safe and effective hospital discharge.
For MRSA cSSTI increased hospital length of stay is the key
cost driver [119]. Therefore, identiﬁcation of early switch and
early discharge opportunities for patients with MRSA cSSTI
hospitalized in Europe could lead to signiﬁcant reductions in
length of stay, thereby providing a mechanism for improving
outcomes and increasing efﬁciency. Together, these changes
have a crucial role in optimizing investment in ﬁxed costs. This
cost-efﬁciency strategy is well recognized as an approach in
healthcare where more patients can receive care with the
same investment in ﬁxed costs [120]. It has been estimated by
a UK-based study that IV to oral switching for eligible patients
can result in an overall saving of £9233 (£32 per patient) by the
hospital [121].
Interim data are available from a retrospective observa-
tional chart review that investigated treatment patterns for
344 patients with MRSA cSSTIs (admitted between 1 July 2010
and 30 June 2011, discharged alive by 31 July 2011) from more
than 400 hospitals throughout 12 European countries [122].
Although the majority of patients were being treated with
targeted IV antibiotics, 29% met the criteria for an early switch
to oral antibiotics and could have been discontinued from their
IV treatment 9  18 days earlier. Moreover, 24% of IV-only
and 16% of IV-to-oral treatment-switched patients met the
criteria for early discharge, with a mean potential for their
length of stay to be reduced by 7  20 days. These data
provide powerful information on the potential for improving
current treatment of these complicated infections so as to
realize the full clinical and ﬁscal beneﬁts of available antimi-
crobial agents. The results of the full analysis are awaited with
interest.
Linezolid after 10 Years of Clinical
Experience
Linezolid, a member of the oxazolidinone family, was ﬁrst
approved by the US Food and Drug Administration and the
European Medicines Agency in 2001. In Europe, linezolid is
indicated to treat nosocomial pneumonia, when known or
suspected to be caused by susceptible Gram-positive bacteria;
community-acquired pneumonia, when known or suspected to
be caused by susceptible Gram-positive bacteria; and cSSTIs,
when microbiological testing has established that the infection
is known to be caused by susceptible Gram-positive bacteria
[2]. Linezolid’s mechanism of action differs from that of other
antibiotic classes. In vitro studies with clinical isolates (including
methicillin-resistant staphylococci, vancomycin-resistant
enterococci, and penicillin-resistant and erythromycin-resis-
tant streptococci) indicate that linezolid is usually active against
multidrug-resistant strains [2,123–125]. Resistance to linezolid
has been reported in enterococci, S. aureus and coagulase-
negative staphylococci (CoNS). This generally has been
associated with prolonged courses of therapy and the pres-
ence of prosthetic materials or undrained abscesses [2].
Although resistance to linezolid remains rare [124,125], it is
most often due to target-site mutation in the 23S rRNA gene
and associated with prolonged and/or intermittent use of
linezolid [126–128]. Outbreaks of linezolid-resistant MRSA,
CoNS and enterococci due to dissemination of resistant clones
have been reported [127,129,130]. An outbreak of linezo-
lid-resistant MRSA due to acquisition of an RNA methyltrans-
ferase resistance gene (cfr) was ﬁrst reported in 2008 [127].
Evidence suggests that horizontal and interclonal transmission
of resistance may occur [127,129,130] through a new mobile
resistance determinant, cfr, that requires close monitoring
[131]. In a global survey conducted in 2011 by the Zyvox
Annual Appraisal of Potency and Spectrum Programme
(ZAAPS), 99–100% of MSSA, MRSA and CoNS isolates were
susceptible to linezolid. The 14 reported resistant strains were
from Brazil (ﬁve), France (one), Germany (two), Greece (two),
Italy (two), Ireland (one) and Spain (one), representing ﬁve
species (Enterococcus faecium, Staphylococcus capitis, Staphylo-
coccus epidermidis, Staphylococcus hominis and Staphylococcus
lugdunensis) [124]. Two of these strains contained the mobile
cfr gene with elevated linezolid MIC values [124].
European surveillance studies show that nearly 99% of
S. aureus isolates are inhibited by linezolid. Surveillance data
from ZAAPS, which monitored linezolid susceptibility from
2003 to 2009, found no evidence of resistance emerging to
linezolid during this 8-year period [132]. In 2011, only 14
(0.06%) of 22 653 S. aureus isolates reported to the EARS-Net
database from 26 European countries were non-susceptible to
linezolid [27]. A surveillance study of antimicrobial resistance
patterns in 21 European countries found that MRSA rates
ranged from 16% (Bulgaria) to 60% (Poland, Romania and
Slovakia). All S. aureus isolates (n = 2413) were susceptible to
linezolid (MIC90 2 mg/L), tigecycline (MIC90 0.12 mg/L) and
vancomycin (MIC90 1 mg/L). Seven isolates of linezolid-resistant
CoNS were noted in ﬁve European nations (France, Greece,
Italy, Romania and Spain) [133]. Vancomycin-resistant S. aureus
has been isolated from very few infections worldwide; however,
the ﬁrst case of vancomycin-resistant S. aureus in Europe was
recently reported in Portugal [134]. This worrying ﬁnding
reinforces the need for continued surveillance, infection control
and antimicrobial stewardship initiatives.
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Since its initial approval, much clinical research data has
been published on the pharmacokinetics, efﬁcacy, safety and
health-economic outcomes of linezolid. For the treatment of
MRSA cSSTIs, non-inferiority trials have conﬁrmed that
linezolid, daptomycin, tigecycline, telavancin and ceftaroline
all demonstrate efﬁcacy comparable to that of vancomycin
with or without aztreonam [72,135–140]. There are no
speciﬁcally designed randomized controlled trials with teicopl-
anin in MRSA cSSTIs, although efﬁcacy has been reported in
several retrospective and prospective studies [141–145].
As proven in clinical trials, linezolid is an effective alternative
to vancomycin for the treatment of culture-conﬁrmed MRSA
cSSTIs [137], including cSSTIs that affect the lower limbs
[146,147]. In a phase IV study of 1077 cSSTI patients with
culture-proven MRSA who were randomized to receive either
vancomycin or linezolid, the clinical success rate of linezolid
was comparable to that of vancomycin in the per-protocol
population and signiﬁcantly higher in the modiﬁed intent-to-
treat population (p 0.048). The microbiological success rate
was signiﬁcantly higher for linezolid at the end of treatment
(p <0.001) [137]. Additionally, patients had a signiﬁcantly
shorter length of hospital stay and duration of IV therapy than
those receiving vancomycin [137]. A post hoc analysis of this
study [148] showed that there was a greater resolution of pain
and inﬂammation with linezolid, as indicated when erythema,
induration, discharge, pain, swelling, tenderness to palpation
and warmth were assessed by a physician [148]. Several studies
have also compared linezolid and vancomycin for the treat-
ment of MRSA cSSTIs localized in the lower extremities
[146,147]. In a single-centre, open-label study linezolid dem-
onstrated signiﬁcantly greater efﬁcacy (higher rates of cure and
improvement at the end of treatment) and shorter length of
hospital stay than vancomycin in patients with lower-extremity
MRSA cSSTIs [146]. Furthermore, no patients required
amputation after having been treated with linezolid (compared
with seven who underwent this surgery after treatment with
vancomycin, p 0.011) [146]. In a retrospective subgroup
analysis based on the phase IV study, fewer surgical interven-
tions were needed for patients treated with linezolid than
vancomycin [149], conﬁrming more favourable patient out-
comes with linezolid in patients with lower-extremity MRSA
cSSTIs.
Managing the Linezolid Patient and Safety
Considerations
Special populations
The unique beneﬁts of linezolid, including its demonstrated
clinical and microbiological efﬁcacy, 100% oral bioavailability,
excellent tissue penetration and lack of requirement for
therapeutic drug monitoring [2,93,104,137], make it an
attractive option for the treatment of patients with cSSTIs,
including those with pre-existing conditions. In patients with
cSSTI and co-morbid vascular disease, penetration of antimi-
crobials can be compromised by poor tissue perfusion, and
clinical success rates are lower than for patients without
vascular disease [147]. However, when compared with
vancomycin, treatment with linezolid leads to higher rates of
clinical (80.4% versus 66.7%, p 0.02) and microbiological
(68.0% versus 56.9%, p 0.07) success in this population
[147]. These data suggest that in patients with vascular
disease, who are at high risk of clinical failure, the selection
of linezolid to treat cSSTI would be beneﬁcial.
For patients with renal insufﬁciency, linezolid represents a
suitable therapeutic choice for the treatment of serious MRSA
infections. Despite a recent report that trough plasma
concentrations of linezolid and subsequent risk of thrombo-
cytopenia are higher in patients with renal impairment
(creatinine clearance <60 mL/min)[150], several other studies
suggest that linezolid elimination does not appear to be
affected by renal function and no dosage adjustment is
warranted for patients with renal impairment [2,137,151,152].
The increase in worldwide obesity poses a particular
problem for the management of infections. Obesity can lead
to consequences for the dosing and pharmacodynamics of
drugs due to the changes it causes in the body, including an
increase in the volume of distribution and alterations to
hepatic metabolism and renal excretion. Dose adjustments
therefore need to be made for certain antibiotics [153,154].
Although serum concentrations of orally administered linezolid
are decreased in obese patients with MRSA cellulitis compared
with healthy volunteers, a prolonged serum inhibitory activity
against common cSSTI pathogens is still maintained [155]. In a
study of IV linezolid in 20 morbidly obese patients, the
clearance, half-life, volume at steady state and AUC (based on
a 12-h dosing schedule) were similar to those in normal-weight
volunteers, implying that dosage adjustment based on body
mass index alone may not be necessary [156].
Safety
Linezolid is the only licensed drug in the oxazolidinone class,
which is a relatively new group of synthetic antibiotics [152].
The safety proﬁle of linezolid has been well documented. The
overall incidence of adverse events is similar to that of
vancomycin and consistent with each drug’s established safety
proﬁle [137]. In a randomized controlled trial of patients with
MRSA cSSTI, 48% of linezolid-treated and 51% of vancomy-
cin-treated patients experienced adverse events. Of these,
23% of adverse events in the linezolid group and 22% in the
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vancomycin group were reported to be related to the
treatment. Treatment-related haematological adverse events
were low in both groups and no treatment-related deaths
were recorded for either drug [137].
The safety proﬁle of linezolid has been evaluated in a pooled
analysis of data from seven phase III, multicentre, multinational,
comparator-controlled clinical trials. This enabled the assess-
ment of 2046 patients treated with linezolid and 2001 treated
with one of several comparators (vancomycin, cefpodoxime,
ceftriaxone, oxacillin-dicloxacillin or clarithromycin), 53% of
which had an SSTI. Overall, linezolid was well tolerated when
given via the IV or oral route at doses of up to 600 mg twice
daily for up to 28 days [157]. Approximately 22% of patients
were documented to have experienced adverse events, most
notably headache, diarrhoea, nausea and candidiasis. Discon-
tinuation due to a drug-related adverse event occurred in 2.4%
of patients [2,157]. As with other antibiotics, myelosuppres-
sion (including anaemia, leucopenia, pancytopenia and throm-
bocytopenia) has been reported in patients receiving linezolid
[2]. Thrombocytopenia and anaemia can occur in some
patients who are given linezolid, and in those with underlying
haematological abnormalities or lower baseline parameters,
substantially low haematology values may develop. Data from
clinical trials suggest that myelosuppression is dependent on
the duration of therapy [158]. Thrombocytopenia (reduced
platelet count) and a slight increased risk for anaemia were
evident in patients who had linezolid treatment that exceeded
2 weeks’ duration. These haematological abnormalities were
consistent with mild, reversible, duration-dependent myelo-
suppression [2,158]. Bleeding with thrombocytopenia appears
to be infrequently associated with linezolid. In a study that
evaluated linezolid-induced thrombocytopenia among 19
patients, only one of six thrombocytopenic patients experi-
enced gastrointestinal bleeding [159]. It is recommended that
complete blood counts, including total platelets and differen-
tiated leucocytes, as well as haemoglobin levels should be
monitored weekly in patients who receive linezolid regardless
of their baseline blood count [2] although, in low-risk patients
(normal renal function and normal baseline haematological
parameters) this approach is probably not always necessary. In
addition, following the results of a randomized trial in patients
with catheter-related bloodstream infections [160], it was
clariﬁed in the linezolid label that when treating bacteraemia
that is suspected to have a Gram-negative aetiology, it is
critical that Gram-negative therapy be initiated [2]. Therefore,
in cSSTIs, linezolid should only be used in patients with known
or possible co-infection with Gram-negative organisms if there
are no alternative treatment options available. In these
circumstances, treatment against Gram-negative organisms
must be initiated concomitantly [2]. Although results from an
in vitro study have suggested antagonism between Gram-posi-
tive and Gram-negative spectrum antimicrobials when used
against E. coli [161], a second in vitro study found that the
combination of linezolid with aztreonam or ceftazidime at
therapeutically relevant drug concentrations was efﬁcacious
(>3-log kill against E. coli by 24 h, with all concentrations
studied), and antagonism between linezolid in combination
with aztreonam or ceftazidime could not be conﬁrmed [162].
To date, there are no further studies that indicate signiﬁcant
drug–drug interactions with aztreonam and linezolid. Although
some other serious adverse events have been reported for
linezolid, this treatment is generally considered safe and well
tolerated [2,157].
Conclusions
The management of cSSTIs is often complicated by their
heterogeneous presentation and microbial, host and local
inﬂuences. The selection of appropriate antimicrobial therapy
must take each of these factors into account, while considering
the implications for the patient’s overall quality of life. Current
treatment options for cSSTI patients with MRSA infections are
limited. Linezolid has proven to be a valuable alternative to
vancomycin, with the advantage that it has an oral formulation
allowing a rapid transition from IV to oral therapy and early
discharge from the hospital. Antimicrobial resistance to
linezolid is rare, and it is a safe and well-tolerated treatment
that also has unique beneﬁts in certain patient populations,
including those with renal or vascular insufﬁciency.
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